Highly Efficient Intracellular Protein Delivery by Cationic Polyethyleneimine-Modified Gelatin Nanoparticles

Materials
Ming-Ju ChouYi-You Huang

Abstract

Intracellular protein delivery may provide a safe and non-genome integrated strategy for targeting abnormal or specific cells for applications in cell reprogramming therapy. Thus, highly efficient intracellular functional protein delivery would be beneficial for protein drug discovery. In this study, we generated a cationic polyethyleneimine (PEI)-modified gelatin nanoparticle and evaluated its intracellular protein delivery ability in vitro and in vivo. The experimental results showed that the PEI-modified gelatin nanoparticle had a zeta potential of approximately +60 mV and the particle size was approximately 135 nm. The particle was stable at different biological pH values and temperatures and high protein loading efficiency was observed. The fluorescent image results revealed that large numbers of particles were taken up into the mammalian cells and escaped from the endosomes into the cytoplasm. In a mouse C26 cell-xenograft cancer model, particles accumulated in cancer cells. In conclusion, the PEI-modified gelatin particle may provide a biodegradable and highly efficient protein delivery system for use in regenerative medicine and cancer therapy.

References

Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·O BoussifJ P Behr
Aug 11, 1998·Biochemical Pharmacology·A R KlemmJ B Lloyd
Jul 30, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·W T GodbeyA G Mikos
Jun 23, 2004·Critical Reviews in Oncology/hematology·Stewart Sell
Mar 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S Moein MoghimiJ Clifford Murray
Mar 4, 2008·Advanced Drug Delivery Reviews·Karina R Vega-VillaNeal M Davies
Oct 22, 2009·Small·Ayush Verma, Francesco Stellacci
Aug 11, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yoshiko UesugiYasuhiko Tabata
May 14, 2011·Chemical Society Reviews·Zhen GuYi Tang
Jul 31, 2013·Acta Biomaterialia·P Charoenphol, H Bermudez
Oct 8, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ahmed O Elzoghby
Nov 21, 2014·Advances in Genetics·Patrick Neuberg, Antoine Kichler
May 7, 2015·Expert Opinion on Drug Delivery·Maytal Foox, Meital Zilberman
Nov 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kwang Hwa JungLaura Beretta
Dec 17, 2016·Biomaterials Research·Eunsol Kim, Giyoong Tae
May 13, 2017·Current Pharmaceutical Design·Mari C EchaveGorka Orive

❮ Previous
Next ❯

Citations

Jul 3, 2020·Pharmaceutics·Seyoung HongHee Ho Park
Apr 3, 2020·Chemical Communications : Chem Comm·Albert HarguindeyJennifer N Cha
Aug 11, 2019·Colloids and Surfaces. B, Biointerfaces·Mohaddeseh Mahmoudi Saber
Jul 1, 2021·International Journal of Nanomedicine·Yueheng WuShunqing Tang
Jul 3, 2021·International Journal of Molecular Sciences·Nikolaos NazirisCostas Demetzos

❮ Previous
Next ❯

Methods Mentioned

BETA
light scattering
electrophoresis
Atomic Force Microscopy
Assay
protein assay
confocal microscopy
transfection
xenograft
flow cytometry
atomic

Software Mentioned

ImageJ

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.